Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


MALVERN, Pa., Jan. 21, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 787,268 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 217,681 shares of common stock to three newly hired team members. The stock options and RSUs were granted on January 10, 2022, and January 17, 2022, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). 687,872 of the stock options and 190,198 of the RSUs were issued on January 10, 2022, to a new member of the management team, whose appointment will be announced at a later date.

The stock options have a ten-year term and exercise prices of $4.32 and $4.25 per share, …

Full story available on Benzinga.com


Please enter your comment!
Please enter your name here